The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Morrell Martha since 2022.
This trader's CIK number is 1855616.
At the time of last reporting, Morrell Martha was the CHIEF MEDICAL OFFICER of Neuropace Inc. (stock ticker symbol NPCE).
Also see all insider trading activities at Neuropace Inc.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | NPCE | 0 | $0 | 81,834 | $1,127,352 | 102,810 | $2,673 |
2024 | NPCE | 0 | $0 | 32,265 | $486,797 | 0 | $0 |
2023 | NPCE | 0 | $0 | 27,137 | $253,142 | 0 | $0 |
2022 | NPCE | 0 | $0 | 0 | $0 | 576 | $14 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-02-12 | NPCE | Option Ex | 50,000 | .03 | 1,300 |
2025-02-21 | NPCE | Sale | 78,334 | 13.72 | 1,074,820 |
2024-01-31 | NPCE | Option Ex | 52,810 | .03 | 1,373 |
2025-01-29 | NPCE | Sale | 100 | 15.00 | 1,500 |
2025-01-30 | NPCE | Sale | 200 | 15.00 | 3,000 |
2025-01-24 | NPCE | Sale | 3,200 | 15.01 | 48,032 |
2024-02-02 | NPCE | Sale | 14,143 | 15.07 | 213,120 |
2024-02-05 | NPCE | Sale | 3,446 | 15.17 | 52,279 |
2024-02-01 | NPCE | Sale | 663 | 15.04 | 9,970 |
2024-01-30 | NPCE | Sale | 11,262 | 15.10 | 169,999 |
2024-01-31 | NPCE | Sale | 1,923 | 15.07 | 28,989 |
2024-01-24 | NPCE | Sale | 827 | 15.03 | 12,425 |
2024-01-25 | NPCE | Sale | 1 | 15.00 | 15 |
2023-12-26 | NPCE | Sale | 102 | 10.00 | 1,020 |
2023-12-27 | NPCE | Sale | 13,300 | 10.12 | 134,649 |
2023-12-20 | NPCE | Sale | 2,730 | 10.14 | 27,695 |
2023-12-06 | NPCE | Sale | 11,005 | 8.16 | 89,778 |
2022-10-07 | NPCE | Option Ex | 576 | .03 | 14 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Morrell Martha (CHIEF MEDICAL OFFICER of Neuropace Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.